How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

20 results for

Triphasil

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Triphasil

Triphasil Triphasil Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Triphasil Triphasil Aka: Triphasil , Trinordiol , Logynon (...) , Trivora , Enpresse II. Preparations (Levonorgestrel / Ethinyl Estradiol - 0.05/30 - 0.075/40 - 0.125/30) Triphasil Logynon (UK) Trivora Enpresse III. Components 0.05 to 0.125 mg (see preparation above) 30 to 40 ug IV. Effect Relative : 0.5 (low) : 28 (moderate) : 0.29 (moderate) V. Pill associated problems (Similar to Ortho-Novum 7/7/7) Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower ) Indications to switch to Tenderness or engorgement (lower ) s (lower

2018 FP Notebook

2. Triphasil

Triphasil Triphasil Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Triphasil Triphasil Aka: Triphasil , Trinordiol , Logynon (...) , Trivora , Enpresse II. Preparations (Levonorgestrel / Ethinyl Estradiol - 0.05/30 - 0.075/40 - 0.125/30) Triphasil Logynon (UK) Trivora Enpresse III. Components 0.05 to 0.125 mg (see preparation above) 30 to 40 ug IV. Effect Relative : 0.5 (low) : 28 (moderate) : 0.29 (moderate) V. Pill associated problems (Similar to Ortho-Novum 7/7/7) Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower ) Indications to switch to Tenderness or engorgement (lower ) s (lower

2015 FP Notebook

3. A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods

. Condition or disease Intervention/treatment Phase HIV Drug: Nur-Isterate Device: Nuvaring Drug: Triphasil Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 131 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Other Official Title: An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options (...) once every 28 days, and removed after 21 days. Device: Nuvaring Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day. Active Comparator: Arm C: Oral This arm will receive Triphasil a daily oral contraceptive of 21 active tablets

2015 Clinical Trials

4. Oral contraceptive formulations

, followed by 7 tablets of ferrous fumarate 75 mg (US: Fe, Warner Chilcott) 35/30/30 µg ethinylestradiol: triphasic ethinylestradiol/desogestrel combination with 7 tablets 35 µg/50 µg, 7 tablets 30 µg/100 µg, 7 tablets 30 µg/150 µg (RU: Tri-Merci, Organon) 30/40/30 µg ethinylestradiol: triphasic ethinylestradiol/levonorgestrel combination with 6 tablets 30 µg/50 µg, 5 tablets 40 µg/75 µg, 10 tablets 30 µg/125 µg (UK: Trinordiol, Wyeth; Logynon, Logynon ED, Bayer; US: Triphasil, Wyeth; Trivora, Watson

2012 Wikipedia

5. Alfalfa

(Contraceptive drugs) Some birth control pills contain estrogen. Alfalfa might have some of the same effects as estrogen. However, alfalfa is not as strong as the estrogen in birth control pills. Taking alfalfa along with birth control pills might decrease the effectiveness of birth control pills. If you take birth control pills along with alfalfa, use an additional form of birth control such as a condom. Some birth control pills include ethinyl estradiol and levonorgestrel (Triphasil), ethinyl estradiol

2009 National Centre for Complementary and Alternative Medicine

6. Biphasic versus triphasic oral contraceptives for contraception. (PubMed)

estradiol. No important differences emerged, and the frequency of discontinuation due to medical problems was similar with all three pills. Percival-Smith 1990 compared a biphasic pill containing norethindrone (Ortho 10/11) with a triphasic pill containing levonorgestrel (Triphasil) and with another triphasic containing norethindrone (Ortho 7/7/7). The biphasic pill had inferior cycle control compared with the levonorgestrel triphasic. The odds ratio of cycles with intermenstrual bleeding was 1.7 (95

2006 Cochrane

7. Biphasic versus triphasic oral contraceptives for contraception. (PubMed)

) with a triphasic pill containing levonorgestrel (Triphasil) and another triphasic pill containing norethindrone (Ortho 7/7/7). The biphasic pill had inferior cycle control compared with the levonorgestrel triphasic pill. The odds ratio of cycles with intermenstrual bleeding was 1.7 (95%CI 1.3-2.2) for the biphasic pill compared with the triphasic levonorgestrel pill. The odds ratio of cycles without withdrawal bleeding was 6.5 (95%CI 3.1-13). In contrast, cycle control with the biphasic pill was comparable

2001 Cochrane

8. Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. (PubMed)

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. This study evaluated the effect of lumiracoxib on the pharmacokinetics and pharmacodynamics of ethinyl estradiol (EE) and levonorgestrel (LN) in Triphasil-28 (a triphasic oral contraceptive). Females stabilized on Triphasil-28 continued on Triphasil-28 alone for another month (Treatment Period 1), then also received lumiracoxib (400 mg daily) or placebo (...) for 28 days each (Periods 2 and 3) in a double-blind crossover design. Plasma pharmacokinetic profiles were assessed on Day 21 of Periods 2 and 3. Progesterone and plasma sex hormone binding globulin (SHBG) concentrations were measured before and 2 hours after Triphasil-28 administration on Day 21 of all three treatment periods. Lumiracoxib had no significant effect on EE or LN pharmacokinetics or on progesterone or SHBG concentrations, indicating that anovulation and Triphasil-28 effectiveness

2004 Journal of clinical pharmacology

9. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. (PubMed)

studied in a North American randomized trial vs. an oral contraceptive (OC) and in total has been evaluated in 3319 women in contraceptive clinical trials. This article explores the impact of perfect vs. imperfect compliance with the contraceptive method on contraceptive efficacy. Previously published data for a transdermal system (Patch, n = 812) and OC (Triphasil, n = 605) users from the North American comparative study were reanalyzed to determine the effect of imperfect use on the contraceptive

2004 Contraception

10. Cycle control on low-dose oral contraceptives: a comparative trial. (PubMed)

Cycle control on low-dose oral contraceptives: a comparative trial. Cycle control was studied comparing the monophasic oral contraceptive Loestrin with three low-dose phasic preparations (Triphasil, Ortho 10/11 and Ortho 7/7/7) in 391 women of whom 300 completed 6 cycles. Loestrin subjects had a rate of occurrence (31% of cycles) for intermenstrual bleeding (IMB) comparable to the rates for subjects on the phasic preparations (36%, 37% and 37%, respectively). Triphasil subjects had lower rates (...) with Triphasil (p less than 0.01). Loestrin, Ortho 10/11 and Ortho 7/7/7 subjects were more likely to report amenorrhea (p less than 0.001) and less likely to report leg cramps (p less than 0.01) compared to those on Triphasil. Triphasil subjects were less likely to report acne than subjects on Ortho 7/7/7 (p less than 0.01).

1990 Contraception

11. Initial selection of oral contraceptives. (PubMed)

Initial selection of oral contraceptives. A prospective, randomized trial compared client experiences with three popular oral contraceptives--Triphasil, Ortho-Novum 7/7/7 and Ortho-Novum 1/35. After one year, no significant relationship was found between the contraceptive prescribed and either breakthrough bleeding or satisfaction with the medication. The monophasic formulation, Ortho-Novum 1/35, was associated with amenorrhea more often.

1990 Journal of Reproductive Medicine

12. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. (PubMed)

The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. This open-label, two-period, crossover study was conducted to evaluate the effect of a single 150 mg dose of fluconazole on the pharmacokinetics of ethinyl estradiol in healthy female subjects.Ten subjects regularly taking Ortho-Novum 7/7/7 (Ortho Pharmaceutical, Raritan, N.J.) and 10 subjects regularly taking Triphasil (Wyeth-Ayerst Laboratories, Philadelphia), which contain ethinyl estradiol

1998 American journal of obstetrics and gynecology

13. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial. (PubMed)

Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial. Three hundred thirteen women participated in an open, multicenter comparison of the incidence of intermenstrual bleeding (breakthrough bleeding and or spotting) associated with the use of three triphasic oral contraceptives. Triphasil (n = 107), containing levonorgestrel and ethinyl estradiol, and Ortho-Novum 7/7/7 (n = 97) and Tri-Norinyl (n = 109), both of which contain (...) norethindrone and ethinyl estradiol, were administered over four cycles for a total of 1141 cycles. The total incidence of intermenstrual bleeding was significantly lower with Triphasil (17.2%) than with Ortho-Novum 7/7/7 (39.5%) or Tri-Norinyl (49.0%). The pattern remained the same when findings were analyzed cycle by cycle and for breakthrough bleeding and spotting separately. The incidence of other side effects was comparable for all regimens. Results of this study demonstrate superior cycle control

1989 American journal of obstetrics and gynecology

14. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. (PubMed)

Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Effects on lipid/lipoprotein metabolism of two triphasic oral contraceptives, Triphasil (ethinyl estradiol/levonorgestrel) and Ortho-Novum 7/7/7 (ethinyl estradiol/norethindrone) were compared in a 12-month controlled, prospective clinical trial. The data indicate that use of both estrogen-progestin preparations were accompanied by increases in cholesterol (...) on lipid metabolism of the triphasic preparations Triphasil and Ortho-Novum 7/7/7 are similar and, given the dynamic balance between the various fractions, are unlikely to impart an adverse cardiovascular risk.

1989 American journal of obstetrics and gynecology

15. Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. (PubMed)

Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. The pharmacokinetics of levonorgestrel (LNG) and ethinylestradiol (EE2) were determined in 24 women (aged 21 to 35 years), following the administration of a single tablet from the second phase of two different triphasic preparations (Triphasil and Trinordiol. Each tablet contained 0.075 mg of LNG and 0.040 mg of EE2. The data were compared to the pharmacokinetics of LNG (...) and EE2 obtained following the oral administration of a hydroalcoholic solution (standard) containing the same steroids and dose. The study consisted of a randomized design in which the three formulations were administered to each of the 24 subjects in a three-period crossover pattern. Blood samples were taken at frequent intervals after dosing. Serum levels of LNG and EE2 were measured by specific radioimmunoassays. The results show that both LNG and EE2 in the Triphasil and Trinordiol tablets

1990 Contraception

16. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. (PubMed)

randomly to an ethinyl estradiol/levonorgestrel formulation (Triphasil) or an ethinyl estradiol/norethindrone formulation (Ortho 7/7/7) and 25 control women (no hormonal contraception) had blood sampled for lipids and lipoproteins pre-trial, and at 3- or 6-cycle intervals for 24 cycles.At cycle 24, control women experienced no significant change from baseline in any variable except apolipoprotein B (apo B). Plasma apo B increased 42% (P < .01), reflecting the LDL apo B increase (42%, P < .01). Both (...) in the Triphasil group (8%, P < .05); no other cholesterol subfractions changed significantly. All cycle-24 lipid and lipoprotein values remained well within respective normal ranges.Although 2-year exposure to the triphasic oral contraceptive formulations changed the lipid risk factors for cardiovascular disease only within normal ranges, there remains potential for long-term health effects when compounded with other risk factors.

1995 International journal of fertility and menopausal studies

17. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use. (PubMed)

The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use. Sixty-one women were randomly assigned to use one of two different triphasic oral contraceptives (OCs), for one year's time (Ortho Novum 777, Ortho Pharmaceutical Corp., Raritan, NJ, and Triphasil, Wyeth Laboratories, Philadelphia, PA), containing the progestins norethindrone and levonorgestrel, respectively. The carbohydrate metabolism was evaluated using the oral glucose tolerance test

1989 Fertility and sterility

18. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. (PubMed)

higher than the mean values of women who had not taken OCs for at least 3 months. In study #1, women received the OC preparation Triphasil. In study #2, women were randomised to one of 3 OC preparations (Triphasil, Ortho 777 or Ortho 10/11). HDL-cholesterol (HDL-C) and LDL-C were measured over time at six months and at 12 months after receiving the study medications. The results show that HDL-C increased in women on Ortho 777 and 10/11 and decreased in women on Triphasil at six months (...) , and these changes were not found at 12 months. The results showed change over time for the LDL-C mean values, in that women not on OCs at the start of the studies had increased LDL-C mean values, and women on OCs at the start of the studies had decreased LDL-C mean values. Further the LDL-C mean values in women not on OCs at the start of the studies who received Triphasil (containing the gonane progestin dl-norgestrel) increased over time, whereas the combined mean values of those who received Ortho 777

1987 Contraception

19. A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00236795 Recruitment Status : Completed First Posted : October 12, 2005 Last Update Posted : June 8, 2011 Sponsor: Johnson & Johnson

2005 Clinical Trials

20. A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism. (PubMed)

A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism. This study assessed serum lipid, lipoprotein and apolipoprotein changes during one year in 3 groups of nonsmoking women: 1) Triphasil(R); 2) Ortho(R) 7/7/7; 3) Controls. Both oral contraceptives contain the estrogen, ethinyl estradiol(EE), in combination with a progestin in three different ratios during each cycle. The progestin in Triphasil is d-norgestrel, as the dl (...) -racemate norgestrel (NG), whereas that in Ortho 7/7/7 is norethindrone(NE). Total plasma triglycerides were elevated significantly from baseline (p < 0.001) with Ortho 7/7/7 at 3, 6 and 12 months, but only at 3 months with Triphasil, p = 0.047. Triglycerides were elevated in the LDL fraction with Ortho 7/7/7 at 3 months (p = 0.001), 6 months (p = 0.018) and 12 months (p = 0.010). In contrast, LDL triglycerides were not significantly elevated with Triphasil. Similarly, IDL triglycerides were elevated

1993 Contraception

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>